Sinan Koca1, Mehmet Beşiroğlu2, Melike Özçelik3, Mustafa Karaca4, Mehmet Bilici5, Bekir Hacıoğlu6, Gamze G Doğu7, Nihal B Kaplan8, Zeynep Oruç9, Dinçer Aydın10, Faysal Dane2. 1. Department of Medical Oncology, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey. 2. Department of Medical Oncology, Pendik Training and Research Hospital, Marmara University, Turkey. 3. Department of Medical Oncology, Istanbul Umraniye Training and Research Hospital, University of Health Sciences, Turkey. 4. Department of Medical Oncology, Gazi University, Ankara, Turkey. 5. Department of Medical Oncology, Atatürk University, Erzurum, Turkey. 6. Department of Medical Oncology, Trakya University, Edirne, Turkey. 7. Department of Medical Oncology, Pamukkale University, Denizli, Turkey. 8. Department of Medical Oncology, İnönü University, Malatya, Turkey. 9. Department of Medical Oncology, Dicle University, Diyarbakır, Turkey. 10. Department of Medical Oncology, Dr. Lutfi Kirdar Education and Research Hospital, Istanbul, Turkey.
Abstract
PURPOSE: Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. MATERIALS AND METHODS: We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. RESULTS: The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade ≥3 toxicities were fatigue, anorexia, weight loss, and liver disorder. CONCLUSION: Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.
PURPOSE: Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. MATERIALS AND METHODS: We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. RESULTS: The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade ≥3 toxicities were fatigue, anorexia, weight loss, and liver disorder. CONCLUSION:Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.
Authors: Bader Alshamsan; Ahmad Badran; Aisha Alshibany; Fatma Maraiki; Mahmoud A Elshenawy; Tusneem Elhassan; Jean Paul Atallah Journal: Cancer Manag Res Date: 2021-08-29 Impact factor: 3.989